Evidence map›Paper›PMID 42633333›Full record

ArticleCureus2026

Celecoxib: Not So Harmless?

Ousmane Kaba, Bouchra Chahboun, Maman Idi Chazali, Houssam Bkiyar, Brahim Housni

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ousmane KabaDepartment of Anesthesiology and Intensive Care Unit, Mohammed VI University Hospital, Oujda, MAR.
Bouchra ChahbounDepartment of Anesthesiology and Intensive Care Unit, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University, Oujda, MAR.
Maman Idi ChazaliDepartment of Anesthesiology and Intensive Care Unit, Mohammed VI University Hospital, Oujda, MAR.
Houssam BkiyarDepartment of Anesthesiology and Intensive Care Unit, Mohammed VI University Hospital, Oujda, MAR.
Brahim HousniDepartment of Anesthesiology and Intensive Care Unit, Mohammed VI University Hospital, Oujda, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxic epidermal necrolysis (TEN) is a severe and potentially fatal cutaneous reaction secondary to the use of drugs, including celecoxib. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that is widely prescribed to relieve arthralgia because of its better gastrointestinal tolerance. However, it may also be responsible for skin reactions, most of which are benign. Serious cutaneous adverse reactions have been reported in the form of acute generalized exanthematous pustulosis (AGEP). TEN secondary to celecoxib is poorly documented. Discontinuation of the suspected or causative drug(s), transfer of the patient to a specialist unit as quickly as possible, and supportive care are the cornerstones of patient management.

Indexed as

adverse drug reactionscelecoxibtherapeutic emergencytoxic epidermal necrolysistoxidermia

Identifiers

PMID42633333
PMCPMC13499634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.